脲基取代苯磺酰胺碳酸酐酶抑制剂在体外和体内均具有较强的抗肿瘤作用。

IF 13.5 1区 医学 Q1 HEMATOLOGY
Giorgia Gazzaroli, Camilla Tavani, Serena Filiberti, Maria Luisa Massardi, Marta Turati, Giulia Garattini, Thomas S Peat, Giuseppe Pieraccini, Andrea Angeli, Claudiu T Supuran, Fabrizio Carta, Arianna Giacomini, Roberto Ronca
{"title":"脲基取代苯磺酰胺碳酸酐酶抑制剂在体外和体内均具有较强的抗肿瘤作用。","authors":"Giorgia Gazzaroli, Camilla Tavani, Serena Filiberti, Maria Luisa Massardi, Marta Turati, Giulia Garattini, Thomas S Peat, Giuseppe Pieraccini, Andrea Angeli, Claudiu T Supuran, Fabrizio Carta, Arianna Giacomini, Roberto Ronca","doi":"10.1186/s40164-025-00690-z","DOIUrl":null,"url":null,"abstract":"<p><p>Carbonic anhydrase IX (CA IX) is a tumor-specific metallo-enzyme upregulated during hypoxic conditions and implicated in several pathophysiological processes where tissue pH regulation is required such as cancer, cell invasion, metastatic and stem-like features, drug resistance and recurrence. Indeed, CA IX expression has been correlated with poor prognosis, aggressiveness and disease progression in several solid tumors, and its targeting has been proposed as a therapeutic approach to treat aggressive cancers. To date, several CA IX targeting approaches have been developed to inhibit its activity in neoplastic tissues including the clinical grade (Phase Ib/II) ureido-substituted benzenesulfonamide SLC-0111, which has been widely investigated over the past years. In this study, we carried out a detailed characterization of a SLC-0111 derivative, FC-531, evaluating its anti-tumor potential in parallel with SLC-0111 on a panel of human cell lines representative of different cancer types. Finally, we evaluated the safety profile of FC-531 in vivo and demonstrated its capacity to reduce tumor growth and metastatization in vivo. Together, our data provide the rationale for the exploitation of FC-531 as a potent CA IX inhibitor for the management of different CA IX- expressing solid tumors.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"14 1","pages":"104"},"PeriodicalIF":13.5000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333284/pdf/","citationCount":"0","resultStr":"{\"title\":\"An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo.\",\"authors\":\"Giorgia Gazzaroli, Camilla Tavani, Serena Filiberti, Maria Luisa Massardi, Marta Turati, Giulia Garattini, Thomas S Peat, Giuseppe Pieraccini, Andrea Angeli, Claudiu T Supuran, Fabrizio Carta, Arianna Giacomini, Roberto Ronca\",\"doi\":\"10.1186/s40164-025-00690-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Carbonic anhydrase IX (CA IX) is a tumor-specific metallo-enzyme upregulated during hypoxic conditions and implicated in several pathophysiological processes where tissue pH regulation is required such as cancer, cell invasion, metastatic and stem-like features, drug resistance and recurrence. Indeed, CA IX expression has been correlated with poor prognosis, aggressiveness and disease progression in several solid tumors, and its targeting has been proposed as a therapeutic approach to treat aggressive cancers. To date, several CA IX targeting approaches have been developed to inhibit its activity in neoplastic tissues including the clinical grade (Phase Ib/II) ureido-substituted benzenesulfonamide SLC-0111, which has been widely investigated over the past years. In this study, we carried out a detailed characterization of a SLC-0111 derivative, FC-531, evaluating its anti-tumor potential in parallel with SLC-0111 on a panel of human cell lines representative of different cancer types. Finally, we evaluated the safety profile of FC-531 in vivo and demonstrated its capacity to reduce tumor growth and metastatization in vivo. Together, our data provide the rationale for the exploitation of FC-531 as a potent CA IX inhibitor for the management of different CA IX- expressing solid tumors.</p>\",\"PeriodicalId\":12180,\"journal\":{\"name\":\"Experimental Hematology & Oncology\",\"volume\":\"14 1\",\"pages\":\"104\"},\"PeriodicalIF\":13.5000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333284/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental Hematology & Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40164-025-00690-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40164-025-00690-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

碳酸酐酶IX (CA IX)是一种肿瘤特异性的金属酶,在缺氧条件下上调,并涉及一些需要组织pH调节的病理生理过程,如癌症、细胞侵袭、转移和茎样特征、耐药和复发。事实上,在几种实体肿瘤中,CA IX表达与预后不良、侵袭性和疾病进展相关,并且其靶向性已被提出作为治疗侵袭性癌症的一种治疗方法。迄今为止,已经开发了几种CA IX靶向方法来抑制其在肿瘤组织中的活性,包括临床级(Ib/II期)脲基取代苯磺酰胺SLC-0111,该药物在过去几年中已被广泛研究。在这项研究中,我们对SLC-0111衍生物FC-531进行了详细的表征,并在代表不同癌症类型的人类细胞系上评估了其与SLC-0111并行的抗肿瘤潜力。最后,我们评估了FC-531在体内的安全性,并证明了其在体内减少肿瘤生长和转移的能力。总之,我们的数据为开发FC-531作为一种有效的CA IX抑制剂来治疗不同表达CA IX的实体瘤提供了理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo.

Carbonic anhydrase IX (CA IX) is a tumor-specific metallo-enzyme upregulated during hypoxic conditions and implicated in several pathophysiological processes where tissue pH regulation is required such as cancer, cell invasion, metastatic and stem-like features, drug resistance and recurrence. Indeed, CA IX expression has been correlated with poor prognosis, aggressiveness and disease progression in several solid tumors, and its targeting has been proposed as a therapeutic approach to treat aggressive cancers. To date, several CA IX targeting approaches have been developed to inhibit its activity in neoplastic tissues including the clinical grade (Phase Ib/II) ureido-substituted benzenesulfonamide SLC-0111, which has been widely investigated over the past years. In this study, we carried out a detailed characterization of a SLC-0111 derivative, FC-531, evaluating its anti-tumor potential in parallel with SLC-0111 on a panel of human cell lines representative of different cancer types. Finally, we evaluated the safety profile of FC-531 in vivo and demonstrated its capacity to reduce tumor growth and metastatization in vivo. Together, our data provide the rationale for the exploitation of FC-531 as a potent CA IX inhibitor for the management of different CA IX- expressing solid tumors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
12.60
自引率
7.30%
发文量
97
审稿时长
6 weeks
期刊介绍: Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信